The Expectation Engine That Determines Whether You Scale or Spend 18 Months Putting Out Fires Your investors are not impatient. They're doing math. That's the whole finale. Founders love to frame a demanding board as emotional, short-sighted, or "not getting it." Usually they're none of those things. They're looking at a return that lives or dies on time, and your commercialization timeline is the variable making their spreadsheet sweat. This is Step 12, the final step of the

The Internal Operating System That Determines Whether You Scale or Collapse Under Your Own Weight Every step of this program so far has pointed outward: the market, the buyers, the partners, the hospitals. This one points at the thing most likely to sink you. Which is the company you built to chase all of it. Here's the uncomfortable version. Somewhere on LinkedIn right now, a founder is proudly listing themselves as head of sales, head of customer success, head of partnershi

The Multiplier That Turns Early Traction Into Market Momentum There's a slide in nearly every MedTech deck labeled "Partners." It's a wall of logos sorted by prestige. Most of them have never moved a single unit. That's the trap. In the U.S. market, a partnership is either a multiplier or a distraction wearing a press release. There is no middle ground. And the odds aren't your friend. The failure rate for strategic alliances is famously grim, commonly pegged at around half.

The Factor That Makes or Breaks Renewals, Expansions, and Long-Term U.S. Adoption The first sale gets all the attention. It's the LinkedIn post. The celebratory email. The board slide with another hospital logo added to the pipeline because apparently one contract means world domination now. Unfortunately, it's also the sale that's most likely losing you money. Step 8 was about getting a hospital live. Step 9 is about making sure they never want to leave. Launch is an event.

You Sold the Hospital! Now the Real Work Begins. One of my favorite memories from my time as a clinical specialist went something like this. My phone would ring. "Hey Rob, good news. We sold a robot." "Awesome. Where?" "Hospital X." "Nice. When do they want to launch?" "Tomorrow." "...Tomorrow?" "Yep." My facial expression after I get the news of an urgent launch so the capital rep can recognize revenue before the end of the quarter. That was usually the extent of the handoff

Your Product Doesn't Speak for Itself. Neither Does Your Website. One of the biggest myths in MedTech is that great technology sells itself. It doesn't. If it did, hospitals would be full of incredible products that nobody's ever heard of instead of products backed by companies that built strong commercial engines. The reality is much less satisfying. The moment a hospital stakeholder can't immediately explain what your product does, why it matters, and why they should care,

Stop Calling Every Hospital a Prospect. They're Not. One of the fastest ways to waste a year after FDA clearance is convincing yourself every hospital is a prospect. They're not. Some hospitals move quickly. Some move slowly. Some have physician champions who can push a new technology through procurement in a matter of months. Others have enough internal politics to turn a simple pilot into a multi-quarter project. And yet one of the most common mistakes I see in early-stage

The Part Where Enthusiasm Meets Reality and Reality Wins A pitch deck. A sales rep you hired three weeks ago. A pricing slide that got thrown together the night before a board meeting. A VP of Commercial who starts next month. A shiny new logo the leadership team spent four months arguing about. And, naturally, a LinkedIn post announcing your FDA clearance with enough fire emojis to trigger a smoke alarm. Congratulations. According to a shocking number of MedTech startups, yo

There's a sentence I hear from founders that tells me almost everything about how their U.S. launch is going to go. "We're FDA-cleared. We're ready to scale." That's usually the moment I know the next six months are going to hurt. Clearance means your product is safe and effective under controlled conditions. It does not mean it's usable, integrated, supportable, deployable, or anything a hospital IT director would describe as "ready." Those are different problems entirely, a

There’s a moment that happens in almost every hospital sales process. The physician champion finishes explaining why your technology matters clinically. Everyone nods politely. The room feels optimistic. You start mentally calculating future revenue. Then somebody from finance asks: “How does this impact the budget?” And suddenly the entire energy changes. Because now nobody cares how innovative the technology is. They care whether the economics survive scrutiny from people w

Every medtech founder eventually faces the same uncomfortable question: how do we talk about what this product does without overstepping what the FDA cleared us to say? Under-claim, and you waste the evidence you spent millions to generate. Over-claim, and you invite a warning letter, a stalled hospital deal, or both. FDA clearance proves your product is safe. Your documentation proves your company is trustworthy. Here's what U.S. hospitals actually evaluate before they buy.

FDA clearance is not the same thing as commercial readiness. In Step 1 of the MedTech Recovery Program, we break down why clinical data, KOL strategy, study design, and early site selection often fail to translate into real U.S. adoption. Learn how successful MedTech companies build commercially relevant evidence before entering hospital systems, Value Analysis Committees, and skeptical physician workflows.

FDA clearance is not a commercial strategy. It's permission to start building one. That distinction matters more than most international MedTech founders realize until they've already arrived in the U.S. market, pitch deck in hand, expecting momentum. What they find instead: Clinical skepticism Procurement committees Reimbursement walls Hospital IT And Decision-makers with zero emotional investment in their technology. Clearance doesn't protect you from any of that. Over the